Mifepristone Won in Court, But Not Yet in Law

The easiest mistake after a Supreme Court abortion ruling is to confuse a reprieve with peace. Mifepristone, the first drug in the most common two-pill medication abortion regimen, can still be prescribed through telehealth and dispensed by mail or retail pharmacies after the Supreme Court’s May 14, 2026 order preserving current access while Louisiana’s lawsuit against the Food and Drug Administration proceeds, according to the Associated Press¹ and KFF². That is a real victory for abortion-rights supporters and a real operational fact for patients, pharmacies, telehealth clinics and manufacturers. But I do not think the Court settled mifepristone access. It kept the pipes open while the next set of legal fights gathers pressure.

The basic drug-policy architecture is still intact. The FDA, the federal agency that approves drugs and sets safety conditions for their use, approved mifepristone in 2000 and currently permits it for medication abortion through 10 weeks of pregnancy under a Risk Evaluation and Mitigation Strategy, or REMS, a special safety framework for certain drugs, according to the FDA’s mifepristone Q&A³. Under that framework, mifepristone may be dispensed by a certified prescriber or by a certified pharmacy after a prescription from a certified prescriber, and pharmacies must meet program requirements, including the ability to ship using tracking information, according to the FDA³. Telehealth prescribing simply means that a clinician evaluates and prescribes remotely rather than requiring an in-person visit, a model that became central after the FDA removed the in-person dispensing requirement and after states began banning or sharply limiting abortion following the Supreme Court’s 2022 Dobbs decision, which overruled Roe v. Wade and returned broad abortion regulation to the states, as KFF explains⁴.

That architecture survived two Supreme Court moments, but in different ways. In June 2024, the Court unanimously rejected the challenge in FDA v. Alliance for Hippocratic Medicine because the doctors and medical associations suing did not have standing, the constitutional requirement that a plaintiff show a concrete injury caused by the defendant and likely fixable by a court, according to the Court’s opinion⁵. Justice Brett Kavanaugh’s opinion did not decide whether the FDA lawfully approved mifepristone, lawfully changed the drug’s rules in 2016, or lawfully loosened dispensing rules later, according to the same opinion⁵. It said these plaintiffs were not the right parties to bring the case.

That matters. Standing is not a decorative procedural hurdle. The Court rejected a sweeping model in which doctors who do not prescribe mifepristone could ask federal courts to restrict how other doctors prescribe it and how other patients use it, based on downstream objections and claimed burdens, according to FDA v. Alliance for Hippocratic Medicine⁵. If that theory had worked, almost any ideologically committed professional group could try to nationalize a regulatory dispute through a friendly district court. The Court shut that door. Good.

But a locked door is not a demolished building. The live danger now is that better-positioned plaintiffs, especially states, can try a different entrance. Louisiana’s current lawsuit argues that the FDA’s 2023 REMS changes exceeded agency authority and violated the Comstock Act, the 1873 federal law that restricts mailing certain abortion-related materials, according to KFF’s May 2026 summary². On May 1, 2026, the U.S. Court of Appeals for the Fifth Circuit sided with Louisiana at the emergency stage, finding the state likely to succeed on claims that the FDA’s removal of the in-person dispensing requirement was arbitrary and inadequately explained, according to the Fifth Circuit order published by Justia⁶. The Supreme Court then stayed that disruption on May 14, leaving telehealth, pharmacy and mail access in place while the case continues, according to AP¹.

That sequence is the whole story in miniature. Access is stable today because the Supreme Court stopped an immediate shock. Access is vulnerable tomorrow because the underlying merits are still alive.

The strongest counterargument is practical, and I take it seriously. For a patient trying to get care this week, the difference between an in-person dispensing rule and mail access is not academic. The Supreme Court’s stay gives pharmacies, prescribers and telehealth platforms legal breathing room, and the 2024 standing decision made broad national attacks harder by requiring concrete injury rather than moral or policy disagreement, according to the Supreme Court opinion⁵ and Axios’s report on the May 2026 order⁷. I would not call that nothing. I would call it meaningful stabilization.

Still, stabilization is not settlement. The reason is that the remaining routes attack access from several directions at once. One route is administrative law: states can argue the FDA did not adequately justify telehealth, pharmacy or mail rules. Another is federal criminal law: opponents can argue that the Comstock Act bars mailing abortion drugs, while the Justice Department’s Office of Legal Counsel concluded in 2022 that the law does not prohibit mailing mifepristone or misoprostol unless the sender intends unlawful use, according to the OLC memorandum⁸. A third route is state enforcement: states can pursue prescribers, pharmacies or intermediaries for sending pills into jurisdictions with abortion bans or special medication-abortion restrictions, a conflict KFF identifies as central to post-Dobbs telehealth abortion policy, according to KFF⁴.

That last route may become the most important because it can narrow real access without proving mifepristone unsafe. Texas sued a New York doctor accused of prescribing abortion pills by telemedicine to a Texas patient, and a New York judge dismissed Texas’s attempt to enforce a civil judgment in an early test of New York’s shield law, according to AP⁹. KFF reports that Texas and Louisiana have challenged shield-law medication abortion in different ways, and that Mississippi enacted a law scheduled to take effect July 1, 2026, making it unlawful to manufacture, distribute, dispense or prescribe abortion medication, according to KFF¹⁰. Shield laws are state statutes meant to protect clinicians in abortion-protective states from out-of-state investigations or penalties when they provide care to patients elsewhere, and they are now colliding with bans in states that want to stop pills from crossing their borders, according to KFF⁴.

The scale explains why this fight keeps returning. Guttmacher estimated that medication abortions accounted for about 642,700 abortions in 2023, or 63 percent of all abortions in the formal U.S. health care system, up from 53 percent in 2020, according to Guttmacher¹¹. Those figures exclude self-managed abortions outside the formal health care system and pills mailed into states with total abortion bans, according to Guttmacher¹². By the end of 2024, more than one in seven U.S. abortions involved medication pills mailed by shield-law providers into states with bans, six-week limits or telehealth restrictions, according to KFF⁴. Society of Family Planning’s WeCount project reported that by June 2025, 55 percent of telehealth abortions were provided under shield laws, according to the project’s June 2025 data release¹³.

The safety record is the best argument for FDA deference, but it is not a force field. The National Academies’ 2018 review found that legal abortion methods in the United States, including medication abortion, are safe and effective and that serious complications are rare, according to the National Academies¹⁴. The FDA says its current mifepristone rules retain safeguards, including certified prescribers, certified dispensing and emergency-care access requirements, according to the FDA³. I think that makes a sweeping safety-based attack on the drug weak on the merits. But state sovereignty, mailing-law and provider-liability theories do not need to win a scientific debate over complication rates. They need to make distribution risky, fragmented and expensive.

So my verdict is narrow but firm: the Court preserved mifepristone access for now, and the 2024 standing decision made the crudest national attack harder, but the legal fight has moved rather than ended. The next indicator to watch is not another abstract statement about mifepristone’s safety. It is whether the Fifth Circuit, and then likely the Supreme Court, accepts Louisiana’s state-injury theory or Comstock theory in a final posture. If either theory survives merits review, mail and telehealth access could be cut back nationally even while mifepristone remains FDA-approved. If both fail, and shield-law providers keep supplying a large share of telehealth abortions through 2026, then I will change my view: at that point, the Court will have done more than buy time. It will have helped make the current system durable.